Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Roche
Thumbnail
August 11, 2022

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Thumbnail
August 10, 2022

Gemini's Disc(ontinuation)

Article image
Vantage logo
August 10, 2022

After Astra’s exit Zentalis doubles down on Wee1

Article image
Vantage logo
August 09, 2022

Uniqure’s Huntington’s hopes take a hit

Article image
Vantage logo
August 08, 2022

US drug pricing reform happens at last

As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.

Article image
Vantage logo
August 05, 2022

Sanofi keeps its eye on the China prize with Innovent deal

Article image
Vantage logo
August 03, 2022

It’s official: Roche is a Car-T player

Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.

Article image
Vantage logo
August 02, 2022

Corporate venture investors stay strong

The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.

Article image
Vantage logo
August 02, 2022

Roche tries to jump ahead with subcutaneous Tecentriq

Article image
Vantage logo
August 01, 2022

US FDA approval tracker: July 2022

Article image
Vantage logo
July 29, 2022

No place for Wee1 in Astra’s synthetic lethality work

Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.